{"a":[{"_":"Travere CEO Eric Dube to step down after transforming the rare disease biotech","$":{"href":"/pharma/travere-ceo-eric-dube-step-down-after-transforming-rare-disease-biotech","hreflang":"en"}}]}

Summary

Travere Therapeutics CEO Eric Dube is stepping down to focus on health and family; Bradley Campbell, formerly of Amicus Therapeutics, will assume the role. Dube led the company's rebranding and oversaw the launch of rare kidney disease drug Filspari.